MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Conditions

• Plexiform Neurofibroma
• Neurofibromatosis Type 1 (NF1)

Interventions

• DRUG: Mirdametinib (PD-0325901) oral capsule or dispersible tablet

Sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany